Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans
Newsquawk Staff ·
Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans.
What it means
State attorneys general have moved aggressively on technology platforms in recent cycles, often in coordinated multistate actions, and suits against unlisted or newly prominent targets tend to function as much as positioning for settlement and policy leverage as as live litigation. The claim here rests on misrepresentation and consumer harm, a framing that historically allows a broad evidentiary net and a long runway, with discovery and remedies matters that play out over quarters rather than sessions. OpenAI is not publicly traded, so the transmission channel into equities runs through its largest backer and distribution partner, Microsoft, where exposure is material to the AI build-out narrative but where past regulatory actions against partner or portfolio entities have tended to leave the equity unmoved unless remedies touch revenue sharing, data access, or the underlying product. The Paxton office has prior form in high-profile technology litigation, including actions against the large platforms, and its filings have on occasion served as templates that other states later joined. Worth watching is whether additional states or federal agencies adopt parallel claims, since multistate coordination has historically been the point at which such suits begin to carry financial rather than reputational weight. As a single-state filing against a private target, the initial signal is directional at most.
Sources
- OpenAI reveals plans for an in-house exabyte-scale storage system
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years
- Newsquawk Daily European Opening News - 23rd October 2026
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT
Related headlines
- Newsquawk Weekly Economic Release 26th - 30th October 2026 4 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL1 hour ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS2 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter2 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)3 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed4 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce4 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders5 hours ago
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand18 hours ago
- US President Trump posts "Senator Roger Marshall of Kansas has done an incredible job in representing his Great State! Because of him....Bombardier is investing 270 MILLION DOLLARS, creating THOUSANDS of American Jobs in Kansas, Texas, and Indiana"14 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 20272 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer5 hours ago
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation5 hours ago
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM6 hours ago
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months7 hours ago